GERN Jan 2026 5.000 call
| Previous close | 1.5000 |
| Open | 1.4500 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 5.00 |
| Expiry date | 2026-01-16 |
| Day's range | 1.4500 - 1.5000 |
| Contract range | N/A |
| Volume | |
| Open interest | 275 |
Business WireGeron Corporation Reports First Quarter 2024 Financial Results and Business Highlights
FOSTER CITY, Calif., May 02, 2024--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies, today reported financial results and business highlights for the first quarter 2024.
Business WireGeron to Announce First Quarter 2024 Financial Results on May 2, 2024
FOSTER CITY, Calif., April 25, 2024--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that it will release its first quarter 2024 financial results and business highlights before the market opens on Thursday, May 2, 2024 via press release, which will be available on the Company’s website at www.geron.com/investors. Geron will host a conference call to discuss the financial results as well as business highlights at 8:00 a.m. ET the same day.
Business WireGeron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif., April 18, 2024--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggregate of 243,000 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.
